Results 21 to 30 of about 11,256 (207)

CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer [PDF]

Cancer & Metabolism
Background Small cell lung cancer (SCLC) is a deadly cancer with few treatment options and poor prognosis, creating a dire need for improving therapies. Poly (ADP-ribose) polymerase inhibitors (PARPi) have been tested as a treatment strategy, but patient
Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N. Nair, Vivek Philip, Benjamin H. Lok   +7 more
doaj   +2 more sources

Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes.
Anca Chelariu-Raicu, Sarina A. Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M. Tsimberidou, Funda Meric-Bernstam, Ecaterina E. Dumbrava   +10 more
doaj   +1 more source

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors [PDF]

, 2023
Summary: BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire ...
Rottenberg, Sven, Gogola, Ewa, van den Broek, Bram, Jimenez, Connie R, Bhin, Jinhyuk, Wessels, Lodewyk F A, Roderick L. Beijersbergen, Bram van den Broek, Kaiponen, Taina S, de Bruijn, Roebi, Lieftink, Cor, Alexandra A. Duarte, Christina Andronikou, Sander R. Piersma, Ben Morris, Julian R. de Ruiter, Cor Lieftink, Jonkers, Jos, Jinhyuk Bhin, van der Heijden, Ingrid, Paes Dias, Mariana, Roebi de Bruijn, Morris, Ben, Mariana Paes Dias, Wendy Sol, Piersma, Sander R, Sol, Wendy, Connie R. Jimenez, Ingrid van der Heijden, Jos Jonkers, Marieke van de Ven, Beijersbergen, Roderick L, van de Ven, Marieke, Andronikou, Christina, Lodewyk F.A. Wessels, Duarte, Alexandra A, Sven Rottenberg, de Ruiter, Julian R, Frank Rolfs, Taina S. Kaiponen, Rolfs, Frank, Lara Bakker, Bakker, Lara, Ewa Gogola   +43 more
core   +5 more sources

Fully Automated, High-Dose Radiosynthesis of [18F]PARPi [PDF]

, 2023
peer reviewed[18F]PARPi is currently undergoing clinical trials as a PET tracer for many applications. However, only manual radiosynthesis was reported; this has several drawbacks, including an increased risk of contamination from the operator, and the ...
Herrmann, Ken, Fendler, Wolfgang P, Michael Nader, Pacelli, Anna, Warnier, Corentin, Anna Pacelli, Vriamont, Charles, Thibault Gendron, Otabashi, Muhammad, Nader, Michael, Wolfgang P. Fendler, Fadi Zarrad, Alex Jackson, Ken Herrmann, Charles Vriamont, Gendron, Thibault, Zarrad, Fadi, Corentin Warnier, Jackson, Alex, Muhammad Otabashi   +19 more
core   +1 more source

PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer

Frontiers in Oncology, 2021
Despite the promising activity of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in many cancer types with defects in the DNA damage response the majority of the treated patients acquire PARPi resistance and succumb to their diseases. Consequently,
Antons Martincuks, Jieun Song, Adrian Kohut, Chunyan Zhang, Yi-Jia Li, Qianqian Zhao, Edward Mak, Lorna Rodriguez-Rodriguez, Hua Yu, Mihaela Cristea   +9 more
doaj   +1 more source

Advances in Combined Immunotherapy for Triple Negative Breast Cancer

Zhongliu Fangzhi Yanjiu, 2022
The triple-negative breast cancer has a relatively poor prognosis with limited therapeutic options. This subtype is highly immunogenetic and exhibits rich tumor infiltrated lymphocytes in the tumor microenvironment.
WANG Hua, HU Xiaolei, LI Xingyu, DAI Ying   +3 more
doaj   +1 more source

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors

Journal of Biomedical Science, 2022
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit the concept of synthetic lethality and offer great promise in the treatment of tumors with deficiencies in homologous recombination (HR) repair.
Yu-Yi Chu, Clinton Yam, Hirohito Yamaguchi, Mien-Chie Hung   +3 more
doaj   +1 more source

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system

Frontiers in Genetics, 2022
High-grade serous ovarian carcinoma (HGSOC) is a genomically unstable malignancy responsible for over 70% of all deaths due to ovarian cancer. With roughly 50% of all HGSOC harboring defects in the homologous recombination (HR) DNA repair pathway (e.g ...
Nirashaa T. Bound, Nirashaa T. Bound, Cassandra J. Vandenberg, Cassandra J. Vandenberg, Apriliana E. R. Kartikasari, Magdalena Plebanski, Clare L. Scott, Clare L. Scott, Clare L. Scott, Clare L. Scott   +9 more
doaj   +1 more source

[ ¹⁸ F]PARPi Imaging Is Not Affected by HPV Status In Vitro [PDF]

Molecular Imaging, 2021
Background. Human papillomavirus- (HPV-) associated oropharyngeal squamous cell carcinomas (OPSCCs) are clinically and pathologically distinct from HPV-negative tumors. Here, we explore whether HPV affects functional biomarkers, including γH2AX, RAD51, and PARP1.
Navjot Guru, Paula Demétrio De Souza França, Giacomo Pirovano, Cien Huang, Snehal G. Patel, Thomas Reiner   +5 more
openaire   +3 more sources

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Molecular & Cellular Oncology, 2020
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks.
Jiachen Xuan, Richard B. Pearson, Elaine Sanij   +2 more
doaj   +1 more source